Hypoxic imaging with 99mTc-HL91 single photon emission computed tomography in advanced nonsmall cell lung cancer

Chinese Medical Journal

Volumn 119, Issue 17, 2006, Pages 1477-1480

  Li, Ling ^a,b   Yu, Jin Ming ^a   Xing, Li Gang ^a   Yang, Guo Ren ^a   Sun, Xin Dong ^a   Xu, Jin ^a   Zhu, Hui ^a   Yue, Jin Bo ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Hypoxia; Lung neoplasm; Radiotherapy

Indexed keywords

UPENAZIME TC 99M; DIAGNOSTIC AGENT; OXIME; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 4,9 DIAZA 3,3,10,10 TETRAMETHYLDODECAN 2,11 DIONE DIOXIME; TECHNETIUM TC 99M 4,9-DIAZA-3,3,10,10-TETRAMETHYLDODECAN-2,11-DIONE DIOXIME;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CELL HYPOXIA; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; LUNG TUMOR; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; OXIMES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33748605314     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200609010-00013     Document Type: Article

References (10)

1. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer left 2005; 22: 225-235.
2. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med 2001; 42: 1653-1655.
3. 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys 1998; 42: 737-740.
4. 99mTc-HL91 "hot spot" imaging of mice bearing human carcinoma by gamma camera and the effects of tumor necrosis on imaging. Chin Mad J 2000; 113: 404-407.
5. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, at al. Imaging of hypoxia in human tumors with (F-18)fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212.
6. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, at al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using (F-18) fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-398.
7. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxic imaging with 18F-misonidazole PET in nonsmall cell lung cancer and head and neck cancer before radiotherapy. J Nucl Mad 2005; 46: 253-260.
8. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55: 1233-1238.
9. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59: 971-982.
10. 99mTc-HL91(4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime). Ann Nucl Med 2003; 179: 131-138.